Gene Therapy Company News

We've all heard of companies in the gene therapy space and it's easy to get excited when the news hits. Companies like eGenesis and Adverum have announced some major advances recently, and many more are expected to follow. This article will discuss recent news for these companies, along with those from Thermo Fisher Scientific, Thermo Fisher, and Pharmaron. Here are some examples of some exciting developments and discoveries made by these companies.


One of the most exciting new developments in the field of gene therapy is a company called eGenesis. The company has raised $38 million in a Series A round of funding. The technology is based on pigs and CRISPR gene editing, which is a technique for cutting unwanted genes from a person's DNA. In the past, pig organs have been used unsuccessfully for transplants because of endogenous retrovirus sequences. However, eGenesis scientists have used this tool to remove these genes from pigs' genomes and thereby prepare the way for clinical trials.

The eGenesis team has been working on the next step of the company's development efforts. The company has been innovating using gene editing technologies to develop human-compatible organs, tissues, and cells. The company has also named Michael Curtis, a biopharmaceutical executive with more than 25 years of experience. He is now responsible for the company's xenotransplantation programs and will continue to lead the company's R&D efforts.


The recent Adverum gene therapy company news has shareholders concerned. The company's stock has sunk as much as 20% in premarket trading after the company revised its clinical development plan for ADVM-022, which is designed to reduce the risk of adverse events in patients with diabetic macular edema. Despite the recent setback, the company remains optimistic and may be able to find a path forward.

The company recently announced a setback in its Phase 2 clinical trial of its ADVM-022 gene therapy. Researchers reported that one patient in the study developed hypotony and lost vision in the eye treated with the gene therapy. In response, Adverum unmasked the study and started an investigation to identify the cause of the problems. While the company's progress is encouraging, the new clinical trial may not be ready for FDA approval until 2022.


The Hong Kong-listed gene and cell therapy company Pharmaron recently announced it has acquired the non-clinical CRO Absorption Systems for $137.5 million in cash. The deal adds a range of cell and gene therapy R&D expertise to Pharmaron's already established services in ophthalmology and medical devices. Goetzpartners served as the company's exclusive financial adviser and O'Melveny provided legal counsel.

Absorption Systems' expertise in DMPK/ADME, bioanalysis for small and large molecules, and translational pharmaceutics is complementary to Pharmaron's existing services in ophthalmology and medical devices. This combination of technologies will allow Pharmaron to expand its offering in these fields globally. Furthermore, Absorption Systems will help Pharmaron's customers develop and commercialize their cell and gene therapy products.

Thermo Fisher

Thermo Fisher is buying Brammer Bio, a company specializing in viral vector manufacturing for cell and gene therapy developers. The acquisition comes at a critical time for gene therapies, which are still in the early stages of commercialization. Brammer, headquartered in Cambridge, Massachusetts, will be adding nearly 600 employees to its portfolio. The company is slated to generate $250 million in revenue this year, and hopes to exceed its mid-term market growth rate of 25%.

Thermo Fisher's expansion plans are another sign that the company is firmly committed to developing innovative therapies. In March, the company announced plans to double its bioprocessing capacity at facilities in Massachusetts, Florida, and New Jersey. The company is also doubling its capacity for the production of viral vectors, which are the vehicles for gene therapies. The expansion will also create 200 new jobs. The new facility is the latest investment in the company's gene therapy business. The company is seeing a huge opportunity for gene therapy.

Bespoke Gene Therapy Consortium

In October 2021, the Bespoke Gene Therapy Consortium is launching to generate resources to expedite the development of novel gene therapies for rare diseases. In announcing this news, the FDA, the National Institutes of Health, and ten pharmaceutical companies have teamed up to launch the consortium. The consortium's goals are to speed up the development of gene therapies for rare diseases, such as inherited diseases and cancer.

The Bespoke Gene Therapy Consortium is a public-private partnership of pharmaceutical companies, the FDA, and five nonprofit organizations, with the goal of accelerating the development of customized gene therapies for rare diseases. This new consortium is the first to focus on rare diseases and is part of the AMP Accelerating Medicines Partnership (AMP) program. It will work to create standards to facilitate the development of customized gene therapies.

Publicado en Technology en agosto 17 at 05:24
Comentarios (0)
No login
Inicie sesión o regístrese para enviar su comentario
Cookies on De Gente Vakana.
This site uses cookies to store your information on your computer.